Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDR | P35968 | 2/20 | 0.49 |
| ▸ | PIM1 | P11309 | 2/20 | 0.42 |
| ▸ | PIM3 | Q86V86 | 2/20 | 0.42 |
| ▸ | PIM2 | Q9P1W9 | 2/20 | 0.42 |
| ▸ | TGM2 | P21980 | 2/20 | 0.42 |
| ▸ | PLK4 | O00444 | 2/20 | 0.41 |
| ▸ | RPS6KA3 | P51812 | 1/20 | 0.41 |
| ▸ | CES1 | P23141 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 2/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.41 |
| ▸ | RET | P07949 | 1/20 | 0.41 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.40 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.40 |
| ▸ | SRC | P12931 | 1/20 | 0.40 |
| ▸ | MAP1LC3B | Q9GZQ8 | 1/20 | 0.40 |
| ▸ | RAF1 | P04049 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4013040 | 0.80 | CHEK1 (0.58) | KDRPIM1PLK4RPS6KA3RET | |
| SCHEMBL4014885 | 0.76 | FLT3 (0.53) | KDRRPS6KA3MEN1KMT2APDGFRB | |
| SCHEMBL4013532 | 0.75 | CHEK1 (0.64) | PIM1SRC | |
| SCHEMBL249651 | 0.73 | MEN1 (0.58) | KDRPIM1PLK4MEN1KMT2A | |
| SCHEMBL249650 | 0.73 | MEN1 (0.58) | KDRPIM1PLK4MEN1KMT2A | |
| SCHEMBL2945563 | 0.72 | PLK4 (0.55) | KDRPIM1PIM3PIM2TGM2 | |
| SCHEMBL249353 | 0.72 | PLK4 (0.55) | KDRPIM1PIM3PIM2TGM2 | |
| SCHEMBL13628332 | 0.72 | TGM2 (0.53) | KDRPIM1PIM3PIM2TGM2 | |
| SCHEMBL396431 | 0.70 | PDGFRB (0.71) | KDRPIM1RPS6KA3RETPDGFRB | |
| SCHEMBL396432 | 0.70 | PDGFRB (0.71) | KDRPIM1RPS6KA3RETPDGFRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2009085040-A1 | PROTEIN KINASE INHIBITORS | DCB-USA LLC (US) | 2009-07-09 | — | — | WO | disclosed |
| US-20090163494-A1 | PROTEIN KINASE INHIBITORS | DEVELOPMENT CENTER FOR BIOTECHNOLOGY (TW) | 2009-06-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090163494-A1 | PROTEIN KINASE INHIBITORS | BRAF, MAP3K20, SELENOI | KDR 2756/4885PIM1 602/4885PIM3 667/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.